Sequana Medical announces 2022 Full Year Results and 2023 Outlook
February 09, 2023 01:02 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 CEST alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA1 filing planned for H2 2023DSR®...
Transparency Notifications from Shareholders
February 09, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 am CEST Ghent, Belgium – 09 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer...
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
February 08, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Data from GLPi animal studies demonstrate safety of second-generation DSRii product (DSR 2.0)Data from Phase 1 study of DSR 2.0 in Mexico (CHIHUAHUA) and INDiii filing to US FDA...
Sequana Medical Notice of 2022 Full Year Results and Business Update
February 02, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Ghent, Belgium – 2 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease,...
Sequana Medical announces grant of additional DSR® patent in United States
February 01, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease,...
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023
January 11, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION11 January 2023, 07:00 am CEST Ghent, Belgium – 11 January 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in...
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
November 15, 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION15 November 2022, 07:00 am CET Data from SAHARA with first-generation DSR product (DSR 1.0) confirm: Safe, effective and rapid elimination of...
Sequana Medical to present at Jefferies London Healthcare Conference
November 08, 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 8 November 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease,...
Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
October 25, 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION25 October 2022, 07:00 am CET alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months...
Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting®
October 21, 2022 01:00 ET
|
Sequana Medical NV
Presentation by Dr. Florence Wong on Sunday November 6th in Washington, DC:“An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent...